151 related articles for article (PubMed ID: 7945739)
1. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia.
Miller DD; Flaum M; Arndt S; Fleming F; Andreasen NC
Neuropsychopharmacology; 1994 Aug; 11(1):11-20. PubMed ID: 7945739
[TBL] [Abstract][Full Text] [Related]
2. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia.
Chemerinski E; Ho BC; Flaum M; Arndt S; Fleming F; Andreasen NC
Compr Psychiatry; 2002; 43(5):393-6. PubMed ID: 12216015
[TBL] [Abstract][Full Text] [Related]
3. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.
Kelley ME; van Kammen DP; Allen DN
Am J Psychiatry; 1999 Mar; 156(3):406-11. PubMed ID: 10080556
[TBL] [Abstract][Full Text] [Related]
4. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
Langlois-Thery S; Dollfus S; Lesieur P; Petit M
Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
[TBL] [Abstract][Full Text] [Related]
6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
7. The effect of augmentation with moclobemide on symptoms of schizophrenia.
Silver H; Aharon N; Hausfater N; Jahjah N
Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
[TBL] [Abstract][Full Text] [Related]
8. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
9. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
[TBL] [Abstract][Full Text] [Related]
10. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
11. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
12. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study].
Strzelecki D; Kropiwnicki P; Rabe-Jabłońska J
Psychiatr Pol; 2013; 47(4):609-20. PubMed ID: 24946468
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine has a direct effect on the negative symptoms of schizophrenia.
Tandon R
Hum Psychopharmacol; 2004 Dec; 19(8):559-63. PubMed ID: 15486960
[TBL] [Abstract][Full Text] [Related]
16. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
Schoemaker JH; Jansen WT; Schipper J; Szegedi A
J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
18. [Effects of tobacco on antipsychotic treatments and their symptoms in schizophrenia].
Bouhlel S; Jones Y; Msolly M; Ben Hawala S; El-Hechmi Z
Tunis Med; 2012 Apr; 90(4):311-5. PubMed ID: 22535346
[TBL] [Abstract][Full Text] [Related]
19. [Incidence of the deficit form in refractory schizophrenia].
Samuelian JC
Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
[TBL] [Abstract][Full Text] [Related]
20. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine.
Bodkin JA; Cohen BM; Salomon MS; Cannon SE; Zornberg GL; Cole JO
J Nerv Ment Dis; 1996 May; 184(5):295-301. PubMed ID: 8627275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
